Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AGIO vs PTCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AGIO Captures Overall Composite Edge (58.1 HOLD vs 44.5 HOLD), While PTCT Leads 4–2 on Growth & Valuation Pillars

AGIO Overall Winner 6-Pillar Tally: AGIO 2 – 4 PTCT Matrix Metrics: AGIO 6 – 4 PTCT

As of Nov 16, 2026, Agios Pharmaceuticals, Inc. (AGIO) captures the overall head-to-head institutional edge over PTC Therapeutics, Inc. (PTCT) on higher Unified Composite conviction (58.1/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Options & Positioning), while PTCT wins 4–2 across the 6-pillar growth and valuation breakdown. AGIO trades at $30.42 (2.5x Forward P/E, -297.7% operating margin) versus PTCT at $61.62 (19.9x Forward P/E, 21.5% operating margin).

  • Growth vs. Quality Trade-Off: AGIO earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. PTCT 44.5/100 HOLD) and 1.12β · 85% Vol risk profile, whereas PTCT leads top-line expansion (+69.6% YoY revenue growth, 0.81x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AGIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.4); meanwhile PTCT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AGIO vs PTCT
AGIO NASDAQ Head-to-Head Winner
Agios Pharmaceuticals, Inc.
Pharmaceutical Preparations
$30.42
-3.7% 1D
Market Cap $1.9B
TTM Revenue $141M
Forward P/E 2.5x
Beta / 30D Vol 1.12β · 85% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 81.0 Fund 62.0 Flow 50.0 Mom 53.3
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.2%), weak momentum, RSI 44
RSI-14: 44.4 · SMA20: $33.46 · SMA50: $33.04
PTCT NASDAQ
PTC Therapeutics, Inc.
Pharmaceutical Preparations
$61.62
-2.95% 1D
Market Cap $5.3B
TTM Revenue $1.16B
Forward P/E 19.9x
Beta / 30D Vol 0.81β · 58% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 46.0 Fund 52.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $63.59 · SMA50: $63.97

6-Pillar Scorecard Institutional Category Breakdown (AGIO 2 – 4 PTCT)

Columns: Metric · AGIO · PTCT
1. Valuation Multiples AGIO
Forward P/E 2.5x 19.9x
Trailing P/E 2.5x 19.4x
PEG Ratio N/M 0.81x
EV / Revenue 13.5x 4.7x
2. Growth & Scale PTCT
Revenue Growth (YoY) +330.0% +69.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $141M $1.16B
Market Cap $1.9B $5.3B
3. Profitability & Quality PTCT
Gross Margin N/A 55.2%
Operating Margin -297.7% 21.5%
Net Profit Margin -264.8% -9.2%
Return on Equity (ROE) -33.0% -7740.1%
4. Balance Sheet & Cash Flow PTCT
Cash Generation (TTM) -$414M EBITDA -$41M
Cash Flow Margin N/A -3.6%
Net Cash / Leverage $16.38 Book/Sh · -33.0% ROE $127M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AGIO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 65.7% (16th %ile) 55.7% (17th %ile)
Put/Call OI Skew N/A 0.18x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat PTCT
OpEx & R&D Intensity N/A 33.7% of Rev ($389M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AGIO (6) vs PTCT (4)
Institutional Metric AGIO PTCT Criterion Row Edge
Market Capitalization
Scale
$1.9B $5.3B Larger Scale PTCT
Trailing P/E Ratio
Valuation
2.5x 19.4x Lower Multiple AGIO
Forward P/E Ratio
Valuation
2.5x 19.9x Lower Multiple AGIO
Revenue Growth (YoY)
Growth
+330.0% +69.6% Higher Growth AGIO
Operating Margin (TTM)
Profitability
-297.7% 21.5% Higher Margin PTCT
Net Profit Margin
Profitability
-264.8% -9.2% Higher Margin PTCT
Return on Equity (ROE)
Capital Efficiency
-33.0% -7740.1% Higher ROE AGIO
52-Week Range Position
Momentum
34% ($22–$46) 9% ($59–$91) Stronger Trend AGIO
Beta / 30D Volatility
Risk Regime
1.12β · 85% Vol 0.81β · 58% Vol Lower Realized Risk PTCT
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite AGIO
Trailing 12M Revenue (USD)
Operating Scale
$141M $1.16B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 55.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 13.5x EV/Rev 0.81x PEG · 4.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$414M EBITDA ($16.38 Book/Sh · -33.0% ROE) -$41M ($127M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTCT +6.89 pp
AGIO: -2.87% · PTCT: +4.02%
3M Horizon AGIO +3.59 pp
AGIO: -11.57% · PTCT: -15.16%
6M Horizon AGIO +19.99 pp
AGIO: +7.83% · PTCT: -12.16%
1Y Horizon PTCT +10.7 pp
AGIO: -28.49% · PTCT: -17.79%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AGIO vs PTCT. Trailing 12-month operating profitability (AGIO -297.7% vs PTCT 21.5%) and valuation multiples (AGIO 2.5x vs PTCT 19.9x Forward P/E) are benchmarked directly in Pillar 4 below.

AGIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$141M
Gross MarginN/A
Op. Margin-297.7%
ROE / Fwd P/E-33.0% · 2.5x
PTCT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.16B
Gross Margin55.2%
Op. Margin21.5%
ROE / Fwd P/E-7740.1% · 19.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AGIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 65.7%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AGIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PTCT BREAKDOWN
91d in phase · OBV DISTRIBUTION
Current IV 55.7%
IV Percentile 17th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PTCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AGIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -297.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PTCT Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $5.3B market capitalization and 21.5% operating margin.
OpEx & R&D Reinvestment 33.7% of Rev ($389M)
90D Engineering Disclosures 0 Published

Investor FAQ AGIO vs PTCT Key Questions & Quantitative Answers

As of Nov 16, 2026, Agios Pharmaceuticals, Inc. (AGIO) captures the overall head-to-head institutional edge over PTC Therapeutics, Inc. (PTCT) on higher Unified Composite conviction (58.1/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Options & Positioning), while PTCT wins 4–2 across the 6-pillar growth and valuation breakdown. AGIO trades at $30.42 (2.5x Forward P/E, -297.7% operating margin) versus PTCT at $61.62 (19.9x Forward P/E, 21.5% operating margin). Growth vs. Quality Trade-Off: AGIO earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. PTCT 44.5/100 HOLD) and 1.12β · 85% Vol risk profile, whereas PTCT leads top-line expansion (+69.6% YoY revenue growth, 0.81x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AGIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.4); meanwhile PTCT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PTCT leads the Growth & Scale pillar: AGIO posts +330.0% YoY revenue growth and +0.0% YoY earnings growth on $141M TTM revenue (N/A gross margin, -297.7% operating margin), compared with PTCT at +69.6% YoY revenue growth and +0.0% YoY earnings growth on $1.16B TTM revenue (55.2% gross margin, 21.5% operating margin). On trailing 12-month operating scale, AGIO generates $141M in USD-normalized revenue versus $1.16B for PTCT. In operating R&D and SG&A reinvestment, AGIO deploys N/A (0 90-day corporate R&D disclosures) versus 33.7% of Rev ($389M) (0 disclosures) for PTCT.

AGIO screens cheaper on headline valuation multiples. AGIO trades at 2.5x Forward P/E, 2.5x Trailing P/E, N/M PEG, and 13.5x EV/Revenue (unreported EBITDA margin), whereas PTCT trades at 19.9x Forward P/E, 19.4x Trailing P/E, 0.81x PEG, and 4.7x EV/Revenue (-3.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AGIO (-33.0% ROE) versus PTCT (-7740.1% ROE) capital efficiency.

In options market volatility and institutional positioning, AGIO carries 65.7% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.12β · 85% Vol realized risk). By comparison, PTCT carries 55.7% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.81β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.